Back to Research Hub
NovoCure Limited
NVCR
$17.24+0.39 (+2.31%)
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China.
StreetsValue research for NovoCure Limited (NVCR)
Members get the full report for NovoCure Limited: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.